Previous 10 | Next 10 |
Covid remains a short-term headwind for ClearPoint Neuro's Functional Neuro Navigation segment. There are 45 biopharma partners versus 40 in the previous quarter. PTC-AADC is to commercialize later in the year. Operating losses have declined, and operational efficiency has improve...
Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. N...
SOLANA BEACH, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner PTC Therapeutics for receiving a positive opinio...
SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the ...
The following slide deck was published by ClearPoint Neuro, Inc. in conjunction with this event. For further details see: ClearPoint Neuro (CLPT) Investor Presentation - Slideshow
ClearPoint Neuro's (NASDAQ:CLPT) stock rose ~18% after the company's Q1 results beat analysts' estimates and it raised lower-end of its FY22 revenue outlook a day ago. Net loss narrowed to -$3.96M, compared to -$2.54M in Q1 2021. GAAP EPS of -$0.17, beat estimates by $0.03. Total revenue...
ClearPoint Neuro, Inc. (CLPT) Q1 2022 Earnings Conference Call May 11, 2022 16:30 ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Marc W...
Image source: The Motley Fool. ClearPoint Neuro, Inc. (NASDAQ: CLPT) Q1 2022 Earnings Call May 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: ClearPoint Neuro, Inc. (CLPT) Q1 2022 Earnings Call Transcript
ClearPoint Neuro press release (NASDAQ:CLPT): Q1 GAAP EPS of -$0.17 beats by $0.03. Revenue of $5.03M (+24.8% Y/Y) beats by $0.85M. For further details see: ClearPoint Neuro GAAP EPS of -$0.17 beats by $0.03, revenue of $5.03M beats by $0.85M
SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31,...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene th...
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platfo...
2024-05-25 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...